Erytech Pharma Sa Stock Profit Margin
Erytech Pharma SA fundamentals help investors to digest information that contributes to Erytech Pharma's financial success or failures. It also enables traders to predict the movement of Erytech Stock. The fundamental analysis module provides a way to measure Erytech Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Erytech Pharma stock.
Erytech |
Erytech Pharma SA Company Profit Margin Analysis
Erytech Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Erytech Pharma Profit Margin | (0.03) % |
Most of Erytech Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Erytech Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Erytech Pharma SA has a Profit Margin of -0.0343%. This is 99.69% lower than that of the Biotechnology sector and 99.85% lower than that of the Health Care industry. The profit margin for all United States stocks is 97.3% lower than that of the firm.
Erytech Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Erytech Pharma's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Erytech Pharma could also be used in its relative valuation, which is a method of valuing Erytech Pharma by comparing valuation metrics of similar companies.Erytech Pharma is currently under evaluation in profit margin category among its peers.
Erytech Fundamentals
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.58 X | |||
| Gross Profit | 4.18 M | |||
| EBITDA | (22.69 M) | |||
| Net Income | (228 K) | |||
| Cash And Equivalents | 54.05 M | |||
| Cash Per Share | 1.74 X | |||
| Total Debt | 13.57 M | |||
| Debt To Equity | 1.00 % | |||
| Current Ratio | 2.25 X | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (31.76 M) | |||
| Short Ratio | 0.10 X | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 2.96 | |||
| Number Of Employees | 49 | |||
| Beta | 2.13 | |||
| Market Capitalization | 29.57 M | |||
| Total Asset | 45.81 M | |||
| Retained Earnings | (228 K) | |||
| Working Capital | 30.96 M | |||
| Current Asset | 94.53 M | |||
| Current Liabilities | 9.8 M | |||
| Z Score | 0.48 | |||
| Net Asset | 45.81 M |
Pair Trading with Erytech Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Textron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Textron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Textron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Textron to buy it.
The correlation of Textron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Textron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Textron moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Textron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |